RECURRENT EXTRAPULMONARY NEUROENDOCRINE CARCINOMA

Clinical trials for RECURRENT EXTRAPULMONARY NEUROENDOCRINE CARCINOMA explained in plain language.

Never miss a new study

Get alerted when new RECURRENT EXTRAPULMONARY NEUROENDOCRINE CARCINOMA trials appear

Sign up with your email to follow new studies for RECURRENT EXTRAPULMONARY NEUROENDOCRINE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New hope for Tough-to-Treat cancer: adding immune booster to standard chemo

Disease control Recruiting now

This study is testing if adding an immunotherapy drug called atezolizumab to standard chemotherapy works better for controlling a rare and aggressive type of cancer that starts outside the lungs. It will involve about 189 adults whose cancer has spread and cannot be removed by su…

Matched conditions: RECURRENT EXTRAPULMONARY NEUROENDOCRINE CARCINOMA

Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Mar 30, 2026 14:34 UTC

RECURRENT EXTRAPULMONARY NEUROENDOCRINE CARCINOMA

Get alerted when new RECURRENT EXTRAPULMONARY NEUROENDOCRINE CARCINOMA trials appear

New hope for Tough-to-Treat cancer: adding immune booster to standard chemo